|
1. Biologie
|
|
|
|
|
A Single Cell Shines New Light on How Cancers Develop [NY Times]
|
|
|
|
|
|
The
cell was not a cancer yet. But its state was surprising: It was a cell
that had reverted to an embryonic form, when it could have developed
into any cell type. As it began to divide, cancer genes took over and
the single primitive cell barreled forward into a massive tumor.
|
|
|
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
4.5 Dép., diag. & prono. - Colorectal
|
|
|
|
5.12 Immunothérapies
|
|
|
CRISPR: The Path to Clinical Trials [Xconomy]
|
|
|
|
|
|
Another
application outside the body is in CAR-T cells, white blood cells that
are engineered to fight cancer. CRISPR could permit CAR-T cells from one
donor to be given to many different patients, or improve the safety of
the CAR-T cells, says Leonard. Intellia has entered a partnership with
Novartis to pursue these possibilities.
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
The top 10 (possible) blockbusters that (might) launch this year [FierceBiotech]
|
|
|
|
|
|
-
Atezolizumab, Roche--2020: $2.5 billion. Roche has been positioning
this leading anti-PD-L1 cancer drug, better known as atezo in the biz,
as the third entrant to the hot checkpoint inhibition field. -
Venetoclax, AbbVie/Roche--2020: $1.4 billion. The partners are widely
expected to win a first approval for chronic lymphocytic leukemia, or
CLL, this summer, with solid data from reliable developers aimed at
regulators who have proven very receptive to quick approvals for
oncology drugs.
|
|
|
|
|
|
|
|
|
6.1 Observation
|
|
|
|
6.10 Politiques
|
|
|
Joe Biden's cancer task force to start work next week [STAT]
|
|
|
|
|
|
The
vice president said the task force will work on three key areas:
building on the recent breakthroughs in immunotherapy and other
treatments, sharing data more widely from recent research at cancer
centers, and expanding access to clinical trials.
|
|
|
|
|
|
|
|
|
ASCO Praises President for White House’s Support of “Moonshot” Initiative [ASCO]
|
|
|
|
|
|
ASCO
applauds the President for taking this important step toward making the
“moonshot” vision a reality and for outlining a comprehensive approach
to speed advances in cancer prevention, diagnosis and treatment that
addresses critically important issues, such as patient access to care,
federal funding, and information technology and interoperability of
electronic health records.
|
|
|
|
|
|
|
|
|
6.6 Publications
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
6.8 Communication
|
|
|
|
6.9 Controverses
|
|
|